LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

2005: Europe’s largest medicines biotechnology facilities open: Pfizer Grange Castle, Dublin

16/06/2021

Nominated by: Pfizer 

Organisations in nomination: Pfizer

The Pfizer Grange Castle Biotechnology facility commenced construction in 2000 and was licensed and officially opened in 2005.  It was the first mammalian cell culture facility in Ireland1, and at >1 million square feet, one of the largest integrated biotech facilities in the world.  It fulfilled the need for Enbrel® biological drug substance production capacity and set the stage for rapid growth of the biotech industry in Ireland in the years that followed.

The establishment and success of the Grange Castle facility influenced other companies to set up biotech facilities in Ireland, rendering the country a significant hub for biotech manufacturing1.  It also influenced the Irish government in establishing the National Institute for Bioprocessing Research and Training (NIBRT).  In the years following 2005, the Grange Castle site was chosen to manufacture of one of the world’s most significant vaccines, Prevenar®/Prevnar 13® (for prevention of pneumococcal infections), both drug substance and drug product. In 2021, the site was selected for the manufacture of mRNA-platform drug substances, such as Pfizer’s COVID-19 vaccine.

References:

  • Heavey B. The Medicine Maker. June 29, 2016.
  • Centres for Disease Control and Prevention.
  • Li, X et al. The Lancet. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. January 30, 2021.

 

Share
Alexandra Simionca
Alexandra Simionca
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.